Biogen Idec to add 100 jobs in RTP

Multiple sclerosis and hemophilia drug maker Biogen Idec (Nasdaq: BIIB) will add 100 workers to its operations in Research Triangle Park. The announcement comes on the same day Biogen Idec reported 2014 revenues of $9.7 billion, a 40 percent increase from 2013, and adds to the 1,300 workers already employed by the biotechnology company in the Triangle. Biogen also produces treatments for hemophilia and has grown revenue and employment by more than 50 percent over the past three years and is expecting…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news